TCB (tosyl chloride-berbamine) is a novel, orally active small molecule that efficiently eliminates-positive leukemia in vitro and in vivo.  TCB significantly reduces MYC protein by inhibiting CaMKIIg which is an enzyme critical in stabilizing MYC protein, and induces apoptosis of MYC-positive leukemia cells.  Oral administration of TCB in vivo, significantly eliminated lethal MYC-positive acute lymphoblastic leukemia (ALL) in the orthotopic muse model.  These data demonstrate that TCB is an excellent inhibitor targeting the CaMKIIg/Myc axis for treating MYC-mediated leukemia.